Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Overview of the relationship between ischemia and congestive heart failure
Autore:
Remme, WJ;
Indirizzi:
Sticares Cardiovasc Res Fdn, Res, Rotterdam, Netherlands Sticares Cardiovasc Res Fdn Rotterdam Netherlands otterdam, Netherlands
Titolo Testata:
CLINICAL CARDIOLOGY
fascicolo: 7, volume: 23, anno: 2000, supplemento:, 4
pagine: IV4 - IV8
SICI:
0160-9289(200007)23:7<IV4:OOTRBI>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANGIOTENSIN-CONVERTING-ENZYME; CORONARY-ARTERY DISEASE; LEFT-VENTRICULAR DYSFUNCTION; AVERAGE CHOLESTEROL LEVELS; MYOCARDIAL-INFARCTION; INHIBITORS; TRIAL; MORTALITY; MORBIDITY; ENALAPRIL;
Keywords:
coronary artery disease; angiotensin-converting enzyme inhibitor; left ventricular function; HOPE study; cardiac injury; myocardial infarction;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Remme, WJ Sticare Cardiovasc Res Fdn, Res, Oever 7, NL-3161 GR Rhoon, Netherlands Sticare Cardiovasc Res Fdn Oever 7 Rhoon Netherlands NL-3161 GR
Citazione:
W.J. Remme, "Overview of the relationship between ischemia and congestive heart failure", CLIN CARD, 23(7), 2000, pp. IV4-IV8

Abstract

Ischemic heart disease is the principal etiology of heart failure in the Western world. Myocardial ischemia is important in cardiac remodeling, a process that leads to a progressive change in the shape and size of the heart and significantly worsens the prognosis of patients with heart failure. Preventing ischemic events, therefore, is an important goal in the management of patients with coronary artery disease. Statins have been shown to reducethe number of ischemic events in these patients, whereas the benefit of beta-blocker and aldosterone antagonist therapy on ischemic causes of heart failure remains unclear. Several large trials involving patients with asymptomatic left ventricular dysfunction after myocardial infarction or heart failure have shown that angiotensin-converting enzyme (ACE) inhibitors reducethe incidence of progressive heart failure, death, and ischemic events, thus establishing ACE inhibitors as first-line therapy for these patients. Other lines of evidence have suggested that ACE inhibitor therapy may also benefit patients with preserved left ventricular function, a hypothesis that is being evaluated in three large, controlled, randomized trials. One of these trials, the Heart Outcomes Prevention Evaluation (HOPE) study, was terminated prematurely because it demonstrated the significant positive effectsof the ACE inhibitor ramipril on cardiovascular outcomes in patients with coronary artery disease and preserved left ventricular function. A growing body of data confirms the relationship between ischemia and heart failure and the benefits of ACE inhibitor treatment in abroad range of high-risk patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 09:03:42